Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Defective DNA damage repair leads to chaos in the genome

No. 59 | 12/11/2018 | by Koh

Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now found a cause for the frequent catastrophic events in the genetic material of cancer cells that have only been known for a few years: If an important DNA repair system of the cells has failed, this promotes fragmentation and defective assembly of the genetic material. Cancer cells with such a repair defect can now possibly be treated by a specific group of drugs.

© EMBL / P. Riedinger

Only a few years ago, scientists at the German Cancer Research Center (DKFZ), among others, described a new damage pattern in the genetic material of cancer cells: In a particularly aggressive type of childhood brain tumors, they discovered an unprecedented chaos in the cell nucleus: Sections of individual chromosomes were broken at innumerable points and reassembled incorrectly, so that whole parts were missing, while others were duplicated or incorporated in a wrong orientation. This chromosome catastrophe differed from all previously known genetic defects in tumors.

Scientists use the term chromothripsis to describe such a genetic disaster, which occurs in about twenty to thirty percent of all cancers. The trigger for this has so far been largely unknown. Aurelie Ernst and her team at the German Cancer Research Center have now been able to show that the failure of certain genetic repair systems is one of the causes of chromosomal chaos.

Many environmental influences, such as UV rays, damage the DNA. Cells have an arsenal of mechanisms in place to repair such defects. What happens if one of these repair systems fails? Aurelie Ernst's team tested this on genetically modified mice. In these animals, the tools used by the cell to repair broken DNA double strands were genetically switched off - specifically only in the neural precursor cells.

These mice developed malignant brain tumors (medulloblastomas and high-grade gliomas), which exhibited chromothripsis at a high frequency. The researchers noticed that this is almost always accompanied by extra copies of the Myc oncogene, which is known to be a strong driver of cell growth. "If the DNA repair is defective and Myc nevertheless stimulates the division of these damaged cells, the risk of chaos in the genome is particularly high," explains the DKFZ researcher.

Does this connection between defective genome repair and chromosome chaos also apply to human cancers? Aurelie Ernst and her team can confirm this for brain tumors, melanomas and breast cancer. The researchers also found the involvement of the cancer-promoting Myc in human tumors.

"The chromosome chaos caused by repair defects is frightening at first sight," explains Aurelie Ernst. "However, there are ways to specifically combat cancer cells harboring such defects: We can use drugs to switch off additionally another important DNA repair system. This leads to so much genetic damage that the cell is unable to survive. Healthy cells, on the other hand, which have all their repair systems, don't mind these drugs."

PARP inhibitors are already approved drugs that block a central DNA repair system. It may also be possible to develop other substances that attach to other DNA repair enzymes. "If the analysis of a patient's tumor genome reveals evidence of chromothripsis, treatment with PARP inhibitors could be a new therapeutic option in the future," explains the DKFZ researcher Ernst. "Of course, this has to be confirmed in preclinical and clinical tests.

Manasi Ratnaparkhe, John KL Wong, Pei-Chi Wei, Mario Hlevnjak, Thorsten Kolb, Milena Simovic, Daniel Haag, Yashna Paul, Frauke Devens, Paul Northcott, David TW Jones, Marcel Kool, Anna Jauch, Agata Pastorczak, Wojciech Mlynarski, Andrey Korshunov, Rajiv Kumar, Susanna M Downing, Stefan M Pfister, Marc Zapatka, Peter J McKinnon, Frederick W Alt, Peter Lichter, Aurélie Ernst: Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors.
Nature Communications 2018, DOI: 10.1038/s41467-018-06925-4

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS